Others benefit from microdose GLP-1 protocols that use smaller, more frequent injections, spreading the medication volume across multiple sites to reduce localized burning sensations
While some users report modest weight loss (a few pounds over months), others saw no change on the scale despite feeling slightly less hungry
In May, results of the FLOW trial showed that participants with Type 2 diabetes and chronic kidney disease who received semaglutide had a 24% lower risk of having a major kidney disease event than those receiving a placebo
In addition, approximately 50 decoys were generated for each active compound, providing both positive and negative instances for training and testing (Table 3)
Moderated dosing and timing are everything
This calls for more and larger-sized real-world studies to strengthen the evidence that supports the early use of these combinations to improve cardiovascular outcomes and glycemic control in patients with T2DM